AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6125199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g per day)
Number of subjects: 2
Study 6125199 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg)
Number of subjects: 2
Study 6125199 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100 mg)
Number of subjects: 2
Study 31950378 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 140
Study 31950378 — intervention group
Group type: EXPERIMENTAL
Intervention: FiberSite post luting with Clearfil DC Core Plus (Group 2)
Number of subjects: 140
Study 31950378 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Fiber post luting and core build up with Clearfil DC Core Plus (Group 3)
Number of subjects: 140
Study 31950378 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Fiber post luting with Clearfil DC Core Plus and core build up with Filtek Bulk Fill Posterior (Group 4)
Number of subjects: 140
Study 31950378 — intervention group
Group type: EXPERIMENTAL
Intervention: Specimens that received CAD/CAM crowns after procedures in Groups 2, 3, and 4 (Groups 5, 6, and 7)
Number of subjects: 140
Study 31408150 — intervention group
Group type: EXPERIMENTAL
Intervention: Home pregnancy tests provided to CHWs for free distribution
Number of subjects: 0
Study 31408150 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home pregnancy tests)
Number of subjects: 0
Study 26580123 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 40
Study 26580123 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (HS)
Number of subjects: 40
Study 27283093 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-priced voucher for circumcision
Number of subjects: 1649
Study 27283093 — intervention group
Group type: COMPARATOR
Intervention: Positive-priced voucher for circumcision
Number of subjects: 1649
Study 24129336 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration response imaging (VRI)
Number of subjects: 23
Study 22329774 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal triamcinolone acetonide
Number of subjects: 60
Study 22329774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19021097 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed red blood cell transfusion during feeding
Number of subjects: 22
Study 19021097 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding in anemic infants > 1250 g
Number of subjects: 22
Study 19021097 — intervention group
Group type: COMPARATOR
Intervention: Transfusion without feeding
Number of subjects: 22
Study 17936446 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-attenuated influenza vaccine, trivalent
Number of subjects: 0
Study 17936446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15767500 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 3709
Study 15767500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3709
Study 11985880 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (8 g/day for 5 days)
Number of subjects: 0
Study 10397695 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (r‐hirudin) 0.35 mg/kg
Number of subjects: 17
Study 10397695 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 17
Study 8749149 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg daily
Number of subjects: 8
Study 8749149 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 40 mg daily
Number of subjects: 8
Study 8749149 — intervention group
Group type: COMPARATOR
Intervention: Clemastine 2 mg twice daily
Number of subjects: 8
Study 8749149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2202458 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 97
Study 2202458 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 97
Study 6282302 — intervention group
Group type: COMPARATOR
Intervention: Medium-fibre coarse-bran bread diet (22 g NDF/d)
Number of subjects: 12
Study 6282302 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fibre coarse-bran bread diet (35 g NDF/d)
Number of subjects: 12
Study 6282302 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-fibre fine-bran bread diet (22 g NDF/d)
Number of subjects: 12
Study 6282302 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholemeal bread diet (22 g NDF/d)
Number of subjects: 12
Study 6282302 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse-bran bread diet (22 g NDF/d)
Number of subjects: 12
Study 6282302 — intervention group
Group type: COMPARATOR
Intervention: Low-fibre white bread diet (9 g NDF/d)
Number of subjects: 12
Study 31418933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornus mas extract (CME) 300 mg, 3 capsules per day for 8 weeks
Number of subjects: 84
Study 31418933 — intervention group
Group type: COMPARATOR
Intervention: Starch powder, 3 capsules per day for 8 weeks
Number of subjects: 84
Study 28609534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (3 mg/kg of elemental iron once daily for 12 weeks)
Number of subjects: 80
Study 28609534 — intervention group
Group type: COMPARATOR
Intervention: Iron polysaccharide complex (3 mg/kg of elemental iron once daily for 12 weeks)
Number of subjects: 80
Study 28609534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Number of subjects: 80
Study 28609534 — intervention group
Group type: COMPARATOR
Intervention: Iron polysaccharide complex
Number of subjects: 80
Study 26360834 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate calcium tablets (multiple dosing)
Number of subjects: 36
Study 26360834 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate calcium tablets (single dosing under fasting conditions)
Number of subjects: 36
Study 26360834 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate calcium tablets (single dosing under fed conditions)
Number of subjects: 36
Study 26360834 — intervention group
Group type: COMPARATOR
Intervention: Acamprosate calcium tablets (bioequivalence evaluation)
Number of subjects: 36
Study 23642776 — intervention group
Group type: EXPERIMENTAL
Intervention: EVOO (50ml daily)
Number of subjects: 62
Study 23642776 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained dietary habits)
Number of subjects: 62
Study 21276616 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-Focus (DF) lenses
Number of subjects: 40
Study 21276616 — intervention group
Group type: COMPARATOR
Intervention: Single Vision Distance (SVD) lenses
Number of subjects: 40
Study 19995648 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA)
Number of subjects: 0
Study 19995648 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17785705 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (30, 120, or 180 mg subcutaneously every 4 weeks; 60 or 180 mg every 12 weeks)
Number of subjects: 255
Study 17785705 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 255
Study 17785705 — intervention group
Group type: COMPARATOR
Intervention: IV Bisphosphonates (IV BP)
Number of subjects: 255
Study 14988895 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma radiation treatment (gamma‐RT)
Number of subjects: 130
Study 14988895 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 130
Study 10674758 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild closed head injury (GCS 13-15)
Number of subjects: 31
Study 10674758 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive penetrating head injury (GCS 4-6)
Number of subjects: 31
Study 10674758 — intervention group
Group type: EXPERIMENTAL
Intervention: Blast injuries without direct head trauma
Number of subjects: 31
Study 10674758 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (mild, extensive, blast)
Number of subjects: 31
Study 10674758 — intervention group
Group type: EXPERIMENTAL
Intervention: GCS 13-15 and blast injury groups
Number of subjects: 31
Study 10674758 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive head injury (GCS 4-6)
Number of subjects: 31
Study 10674758 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 31
Study 10674758 — intervention group
Group type: EXPERIMENTAL
Intervention: GCS 4-6 patients
Number of subjects: 31
Study 9056731 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagodana based ORS
Number of subjects: 112
Study 9056731 — intervention group
Group type: COMPARATOR
Intervention: Rice based ORS
Number of subjects: 112
Study 1406416 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/day
Number of subjects: 61
Study 1406416 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 61
Study 1406416 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine 16 g/day
Number of subjects: 61
Study 1406416 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (long-term treatment)
Number of subjects: 61
Study 1406416 — intervention group
Group type: COMPARATOR
Intervention: Resin (long-term treatment)
Number of subjects: 61
Study 1406416 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (12 weeks monotherapy)
Number of subjects: 61
Study 1406416 — intervention group
Group type: COMPARATOR
Intervention: Resin (12 weeks monotherapy)
Number of subjects: 61
Study 3970333 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam 0.25 mg/kg
Number of subjects: 101
Study 3970333 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam 0.5 mg/kg
Number of subjects: 101
Study 3970333 — intervention group
Group type: COMPARATOR
Intervention: Control values (not specified)
Number of subjects: 101
Study 3970333 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of diazepam (0.25 mg/kg and 0.5 mg/kg)
Number of subjects: 101
Study 3970333 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher premedication dose (0.5 mg/kg)
Number of subjects: 101
Study 3970333 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma diazepam levels
Number of subjects: 101
Study 31748169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial treatment
Number of subjects: 3031
Study 31748169 — intervention group
Group type: COMPARATOR
Intervention: Routine diabetes care
Number of subjects: 3031
Study 29474292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessary removal daily
Number of subjects: 137
Study 29474292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessary removal at least weekly
Number of subjects: 137
Study 29474292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessary removal less often than once weekly
Number of subjects: 137
Study 27941661 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus supplementation (500 mg)
Number of subjects: 13
Study 27941661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 24398943 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (BrAC up to 0.6 g/kg for 15 minutes followed by 100 minutes exposure)
Number of subjects: 48
Study 24398943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22520742 — intervention group
Group type: EXPERIMENTAL
Intervention: French version of the QUAL‐E questionnaire
Number of subjects: 372
Study 22520742 — intervention group
Group type: EXPERIMENTAL
Intervention: French version of the MVQOLI questionnaire
Number of subjects: 372
Study 22520742 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trial component
Number of subjects: 372
Study 20831133 — intervention group
Group type: EXPERIMENTAL
Intervention: Formocresol (PDC)
Number of subjects: 120
Study 20831133 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide (CDC)
Number of subjects: 120
Study 19069799 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment including physical factors (a constant magnetic field and negatively polarized phytoaeroions), soft‐tissue manual therapy, and dosed physical exercises.
Number of subjects: 0
Study 15736746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate
Number of subjects: 120
Study 15736746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 12517681 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug withdrawal program
Number of subjects: 25826
Study 10799721 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day continuous accelerated irradiation (CAIR)
Number of subjects: 100
Study 10799721 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (5 days per week)
Number of subjects: 100
Study 8641735 — intervention group
Group type: EXPERIMENTAL
Intervention: Black hypertensive subjects
Number of subjects: 77
Study 8641735 — intervention group
Group type: COMPARATOR
Intervention: White hypertensive subjects
Number of subjects: 77
Study 1563806 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbiturates (high-dose)
Number of subjects: 0
Study 1563806 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbiturates (low-dose)
Number of subjects: 0
Study 1563806 — intervention group
Group type: COMPARATOR
Intervention: Control group (without barbiturates)
Number of subjects: 0
Study 1563806 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbiturates (all patients)
Number of subjects: 0
Study 371650 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. injection of oxytocin 10 u
Number of subjects: 88
Study 371650 — intervention group
Group type: COMPARATOR
Intervention: ergometrine 0.5 mg
Number of subjects: 88
Study 371650 — intervention group
Group type: EXPERIMENTAL
Intervention: continuous infusion of dilute oxytocin
Number of subjects: 88
Study 371650 — intervention group
Group type: COMPARATOR
Intervention: i.v. ergometrine
Number of subjects: 88
Study 371650 — intervention group
Group type: EXPERIMENTAL
Intervention: oxytocin
Number of subjects: 88
Study 30939472 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary IL‐18
Number of subjects: 2377
Study 30939472 — intervention group
Group type: EXPERIMENTAL
Intervention: YKL‐40
Number of subjects: 2377
Study 30939472 — intervention group
Group type: COMPARATOR
Intervention: CVD events
Number of subjects: 2377
Study 30939472 — intervention group
Group type: COMPARATOR
Intervention: All-cause mortality
Number of subjects: 2377
Study 27943617 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative ileus (POI) group
Number of subjects: 108
Study 27943617 — intervention group
Group type: COMPARATOR
Intervention: No postoperative ileus (POI) group
Number of subjects: 108
Study 27943617 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with anastomotic leakage (AL)
Number of subjects: 108
Study 25576433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Number of subjects: 351
Study 25576433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 24313178 — intervention group
Group type: EXPERIMENTAL
Intervention: Double distant space technique (DDS)
Number of subjects: 156
Study 24313178 — intervention group
Group type: COMPARATOR
Intervention: Single space technique (SST)
Number of subjects: 156
Study 21226679 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplement (5 mg melatonin, 225 mg magnesium, and 11.25 mg zinc, mixed with 100 g of pear pulp)
Number of subjects: 43
Study 21226679 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplement (5 mg melatonin, magnesium, and zinc)
Number of subjects: 43
Study 19392928 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF)
Number of subjects: 0
Study 17383527 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (5 mug/kg)
Number of subjects: 80
Study 17383527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 16620649 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nanoparticle dressing (Group A)
Number of subjects: 191
Study 16620649 — intervention group
Group type: COMPARATOR
Intervention: 1% silver sulfadiazine cream (Group B)
Number of subjects: 191
Study 16620649 — intervention group
Group type: COMPARATOR
Intervention: Vaseline gauze (Group C)
Number of subjects: 191
Study 12732773 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesna solution
Number of subjects: 44
Study 12732773 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 44
Study 9862770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (10 mg/70 kg)
Number of subjects: 10
Study 9862770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (20 mg/70 kg)
Number of subjects: 10
Study 9862770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (40 mg/70 kg)
Number of subjects: 10
Study 9862770 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (0.75 mg/70 kg)
Number of subjects: 10
Study 9862770 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (1.5 mg/70 kg)
Number of subjects: 10
Study 9862770 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (3.0 mg/70 kg)
Number of subjects: 10
Study 9862770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7558527 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill low walking (LW)
Number of subjects: 8
Study 7558527 — intervention group
Group type: COMPARATOR
Intervention: Cycle ergometry (BK)
Number of subjects: 8
Study 2178488 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lidocaine i.v.
Number of subjects: 161
Study 2178488 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine combined with venous congestives
Number of subjects: 161
Study 2178488 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilution of etomidate with water (1:1 ratio)
Number of subjects: 161
Study 2178488 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lidocaine with venous congestives
Number of subjects: 161
Study 2178488 — intervention group
Group type: COMPARATOR
Intervention: Remaining groups (without lidocaine)
Number of subjects: 161
Study 2178488 — intervention group
Group type: COMPARATOR
Intervention: Contralateral venous cannula without etomidate
Number of subjects: 161
Study 7203722 — intervention group
Group type: EXPERIMENTAL
Intervention: d,l‐oxyfedrine (Myofedrin)
Number of subjects: 49
Study 7203722 — intervention group
Group type: EXPERIMENTAL
Intervention: l‐oxyfedrine (ildamen)
Number of subjects: 49
Study 7203722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31443627 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates-based exercise treatment (n = 148)
Number of subjects: 222
Study 31443627 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet (n = 74)
Number of subjects: 222
Study 30141776 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 monthly sessions with booster 3 months later (Group 1)
Number of subjects: 40
Study 30141776 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 sessions every 3 months (Group 2)
Number of subjects: 40
Study 30141776 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 27529709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic broadband light (PBBL) plus adapalene gel 0.3%
Number of subjects: 0
Study 27529709 — intervention group
Group type: COMPARATOR
Intervention: Adapalene gel 0.3% monotherapy
Number of subjects: 0
Study 24619106 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate (600 mg)
Number of subjects: 11
Study 24619106 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy products (600 mg)
Number of subjects: 11
Study 24619106 — intervention group
Group type: COMPARATOR
Intervention: Calcium citrate and Dairy products
Number of subjects: 11
Study 22110084 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing stimulation frequency
Number of subjects: 1
Study 22110084 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing stimulation amplitude
Number of subjects: 1
Study 20573799 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake (quintiles: 22, 135, 285, 402, and 656 mg/d)
Number of subjects: 33638
Study 18638410 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathy treatment (n = 15 infants)
Number of subjects: 34
Study 18638410 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 13 infants)
Number of subjects: 34
Study 16022950 — intervention group
Group type: EXPERIMENTAL
Intervention: X-Sizer thrombectomy
Number of subjects: 201
Study 16022950 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCI
Number of subjects: 201
Study 12500862 — intervention group
Group type: EXPERIMENTAL
Intervention: Judgments of nonhuman targets, objects, and concepts
Number of subjects: 6
Study 10513500 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week exercise and educational program
Number of subjects: 41
Study 10513500 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 41
Study 7730703 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 monthly doses of WHO/MDT
Number of subjects: 305
Study 7730703 — intervention group
Group type: COMPARATOR
Intervention: 30 monthly doses of WHO/MDT
Number of subjects: 305
Study 7730703 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 305
Study 2210598 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine orally one hour prior to anesthetic induction
Number of subjects: 56
Study 2210598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine infusion of 0.30 micron/kg/min prior to extracorporeal circulation
Number of subjects: 56
Study 2210598 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nifedipine infusion)
Number of subjects: 56
Study 7378259 — intervention group
Group type: EXPERIMENTAL
Intervention: Debrisoquine (30 mg oral dose)
Number of subjects: 14
Study 7378259 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (75 mg p.o.) given 2 h before debrisoquine
Number of subjects: 14
Study 7378259 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic debrisoquine therapy
Number of subjects: 14
Study 31111502 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy (PRT) with a median dose of 73.8 Gy (RBE; range 68.4-79.2 Gy); 17 patients received adjuvant PRT, 3 received definitive PRT; PRT-only (n=6) or combination PRT/intensity-modulated radiotherapy (IMRT) (n=14)
Number of subjects: 20
Study 28641030 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg E4 combined with 3 mg DRSP
Number of subjects: 396
Study 28641030 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg E4 combined with 3 mg DRSP
Number of subjects: 396